Vertex Pharmaceuticals Incorporated VRTX
Set alert
At close · Oct 30
After hours · Oct 30, 5:48 PM ET
- YTD
- +23.28%
- 1 year
- +33.10%
- Open
- 550.73
- Prev close
- 540.00
- Mkt cap
- 141.56B
- Vol
- 3.03M
- Avg vol
- 1.16M
- EPS
- 17.17
- P/E
- 32.55
- Div yield
- 0.00%
More statistics
- Low
- 549.89
- High
- 563.80
- Forward P/E
- 27.40
- Beta
- 0.28
- Short ratio
- 3.66
- Inst. own
- 98.16%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 2, 2026
- 50-d avg
- 522.84
- 200-d avg
- 478.67
- 1y target
- 571.46
3M chart
Events in this range
- Aug 3, 2026Earnings: 4.73; estimate 4.74; surprise -0.21%
- Aug 4, 2026Rating: Cantor Fitzgerald · Overweight → Overweight
- Aug 4, 2026Rating: TD Cowen · Buy → Buy
- Aug 5, 2026Rating: Barclays · Overweight → Overweight
- Aug 5, 2026Rating: Truist Securities · Buy → Buy
- Sep 28, 2026Rating: UBS · Buy → Buy
- Oct 8, 2026Rating: RBC Capital · Outperform → Outperform
Signals (16)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 28, 2026 | 3 days ago |
| SMA: Bearish | Oct 26, 2026 | 5 days ago |
| SMA: Bullish | Oct 21, 2026 | 1 week ago |
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| MACD: Sell Signal | Oct 1, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 30, 2026 | 1 month ago |
| SMA: Bullish | Sep 22, 2026 | 1 month ago |
| SMA: Bearish | Sep 18, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 4, 2026 | 1 month ago |
| RSI: Overbought | Aug 19, 2026 | 2 months ago |
| RSI: Overbought | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 7, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
Key statistics
- Market cap
- 141.56B
- Enterprise value
- 130.99B
- Trailing P/E
- 32.55
- Forward P/E
- 27.40
- PEG ratio
- 2.11
- Price / sales
- 11.25
- Price / book
- 6.99
- EPS (TTM)
- 17.17
- Beta
- 0.28
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 35.00%
- Revenue (TTM)
- 12.59B
- Revenue growth
- 12.50%
- Free cash flow
- 2.63B
- Total cash
- 7.85B
- Total debt
- 1.98B
- Return on equity
- 23.54%
- Shares outstanding
- 253.30M
- Short % of float
- 1.90%
- 50-day average
- 522.84
- 200-day average
- 478.67
Analyst view
Consensus: buy
- Target (low)
- 350.00
- Target (mean)
- 571.46
- Target (high)
- 667.00
- Strong buy6
- Buy20
- Hold4
- Sell1
- Strong sell1
Next earnings
Nov 2, 2026
Expected Nov 2, 2026. Consensus EPS estimate 4.75.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 2, 2026 | Sep 30, 2026 | 4.80 | — | — | — |
| Aug 3, 2026 | Jun 30, 2026 | 4.74 | 4.73 | -0.01 | -0.21% |
| May 4, 2026 | Mar 31, 2026 | 4.24 | 4.47 | +0.23 | +5.42% |
| Feb 12, 2026 | Dec 31, 2025 | 5.11 | 5.03 | -0.08 | -1.57% |
| Nov 3, 2025 | Sep 30, 2025 | 4.57 | 4.80 | +0.23 | +5.03% |
| Aug 4, 2025 | Jun 30, 2025 | 4.29 | 4.52 | +0.23 | +5.36% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 8, 2026 | RBC Capital | main | Outperform | Outperform |
| Sep 28, 2026 | UBS | main | Buy | Buy |
| Aug 5, 2026 | Truist Securities | main | Buy | Buy |
| Aug 5, 2026 | Barclays | main | Overweight | Overweight |
| Aug 4, 2026 | TD Cowen | main | Buy | Buy |
| Aug 4, 2026 | Cantor Fitzgerald | main | Overweight | Overweight |
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- vrtx.com
News
- Here’s How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years
- Ahead of Vertex (VRTX) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
- Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock
- Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue
- Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
- Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why
- Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
- The $500 Million Non-CF Factor Vertex Investors Can't Ignore on Nov. 2
- Baron Health Care Fund: Q3 2026 New Positions And Exits
- Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change.
Your note
Sign in to keep a note on VRTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALTSHULER DAVID | Officer | Stock Award(Grant) | Jan 21, 2026 | 34,477 |
| ARBUCKLE STUART A | Chief Operating Officer | Stock Award(Grant) | May 12, 2025 | 100,751 |
| ATKINSON EDWARD MORROW III | Chief Technology Officer | Sale | Feb 24, 2026 | 18,432 |
| KEWALRAMANI RESHMA | Chief Executive Officer | Sale | Feb 26, 2026 | 98,278 |
| LEIDEN JEFFREY M | Officer and Director | Stock Award(Grant) | Feb 16, 2026 | 38,784 |
| LIU JOY | Officer | Sale | Jun 30, 2026 | 19,131 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Capital World Investors | 10.29% | 26,115,014 | 14.60B | Jun 29, 2026 |
| Blackrock Inc. | 9.50% | 24,109,373 | 13.47B | Jun 29, 2026 |
| Capital Research Global Investors | 7.68% | 19,490,637 | 10.89B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.53% | 16,580,713 | 9.27B | Jun 29, 2026 |
| State Street Corporation | 4.68% | 11,871,459 | 6.63B | Jun 29, 2026 |
| Invesco Ltd. | 3.17% | 8,043,052 | 4.50B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Growth Fund of America | 5.09% | 12,908,237 | 7.21B | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 8,058,128 | 4.50B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.59% | 6,576,510 | 3.68B | Jun 29, 2026 |
| AMERICAN BALANCED FUND | 2.14% | 5,428,865 | 3.03B | Sep 29, 2026 |
| Invesco QQQ Trust, Series 1 | 2.09% | 5,294,126 | 2.96B | Sep 29, 2026 |
| Amcap Fund | 1.87% | 4,734,921 | 2.65B | Sep 29, 2026 |